Literature DB >> 16570199

Detection of parasitemia profiles by blood culture after treatment of human chronic Trypanosoma cruzi infection.

Ana Maria de Castro1, Alejandro Ostermayer Luquetti, Anis Rassi, Egler Chiari, Lúcia Maria da Cunha Galvão.   

Abstract

The change in parasitemia profile, measured by sequential blood cultures of 27 benznidazole (Bz) treated patients compared with 13 untreated patients, on the chronic phase of chagas disease, is described. All patients were adults (age limits: 23-88) with positive serology (three tests); 23 of them were females. All patients were submitted to six blood cultures, three before and three after Bz treatment. The parasitemia was classified as nondetected (with three negative blood cultures), medium (one positive culture in three), and high (two or three positive cultures). From the eight patients with nondetected parasitemia before Bz, seven still had the same profile and only one switched to medium; from eight with medium parasitemia, seven shifted to nondetected, and one to high parasitemia. From the 11 patients with high parasitemia before Bz, ten converted to nondetected and only one was positive after Bz. Nineteen of the 27 patients changed the parasitemia profile (70.4%), and the rate of therapeutic failure was 11.1% (3/27) during the first 24 months of follow-up after Bz. The shift to nondetected parasitemia profile was from 8/27 to 24/27 patients after Bz treatment for the first 2 years. Only 46.2% (6/13) of the nontreated individuals changed the parasitemia profile. We conclude that there is a strong trypanocide effect of Bz (88.8%) and a rate of therapeutic failure of 11.1% during the first 2 years after trypanocidal treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16570199     DOI: 10.1007/s00436-006-0172-5

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  22 in total

1.  Absence of both circadian rhythm and Trypanosoma cruzi periodicity with xenodiagnosis in chronic chagasic individuals.

Authors:  C Castro; A Prata
Journal:  Rev Soc Bras Med Trop       Date:  2000 Sep-Oct       Impact factor: 1.581

2.  [The behavior of Trypanosoma cruzi parasitemia in chronic chagasics over 13 years].

Authors:  C Castro; V Macêdo; A Prata
Journal:  Rev Soc Bras Med Trop       Date:  1999 Mar-Apr       Impact factor: 1.581

3.  Parasite persistence correlates with disease severity and localization in chronic Chagas' disease.

Authors:  L Zhang; R L Tarleton
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

4.  Amplification of a Trypanosoma cruzi DNA sequence from inflammatory lesions in human chagasic cardiomyopathy.

Authors:  E M Jones; D G Colley; S Tostes; E R Lopes; C L Vnencak-Jones; T L McCurley
Journal:  Am J Trop Med Hyg       Date:  1993-03       Impact factor: 2.345

5.  [Hemoculture: sensitive technique in the detection of Trypanosoma cruzi in chagasic patients in the chronic phase of Chagas disease].

Authors:  Z M Luz; M G Coutinho; J R Cançado; A U Krettli
Journal:  Rev Soc Bras Med Trop       Date:  1994 Jul-Sep       Impact factor: 1.581

6.  Sensitive detection and schizodeme classification of Trypanosoma cruzi cells by amplification of kinetoplast minicircle DNA sequences: use in diagnosis of Chagas' disease.

Authors:  N R Sturm; W Degrave; C Morel; L Simpson
Journal:  Mol Biochem Parasitol       Date:  1989-03-15       Impact factor: 1.759

7.  Hemocultures for the parasitological diagnosis of human chronic Chagas' disease.

Authors:  E Chiari; J C Dias; M Lana; C A Chiari
Journal:  Rev Soc Bras Med Trop       Date:  1989 Jan-Mar       Impact factor: 1.581

8.  Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.

Authors:  A L de Andrade; F Zicker; R M de Oliveira; S Almeida Silva; A Luquetti; L R Travassos; I C Almeida; S S de Andrade; J G de Andrade; C M Martelli
Journal:  Lancet       Date:  1996-11-23       Impact factor: 79.321

9.  Evaluation of the xenodiagnosis of chronic Chagas patients infected ten years or over in an area where transmission has been interrupted--Iguatama and Pains, west Minas Gerais State, Brazil.

Authors:  J R Coura; L L de Abreu; H P Willcox; W Petana
Journal:  Mem Inst Oswaldo Cruz       Date:  1991 Oct-Dec       Impact factor: 2.743

10.  Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up.

Authors:  R Viotti; C Vigliano; H Armenti; E Segura
Journal:  Am Heart J       Date:  1994-01       Impact factor: 4.749

View more
  13 in total

Review 1.  Kinetoplastids: related protozoan pathogens, different diseases.

Authors:  Ken Stuart; Reto Brun; Simon Croft; Alan Fairlamb; Ricardo E Gürtler; Jim McKerrow; Steve Reed; Rick Tarleton
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

2.  Chagas disease: increased parasitemia during pregnancy detected by hemoculture.

Authors:  Liliane da Rocha Siriano; Alejandro Ostermayer Luquetti; Juliana Boaventura Avelar; Neusa Leal Marra; Ana Maria de Castro
Journal:  Am J Trop Med Hyg       Date:  2011-04       Impact factor: 2.345

Review 3.  Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection.

Authors:  Juan Carlos Villar; Juan Guillermo Perez; Olga Lucia Cortes; Adelina Riarte; Micah Pepper; Jose Antonio Marin-Neto; Gordon H Guyatt
Journal:  Cochrane Database Syst Rev       Date:  2014-05-27

4.  A serological, parasitological and clinical evaluation of untreated Chagas disease patients and those treated with benznidazole before and thirteen years after intervention.

Authors:  Girley Francisco Machado-de-Assis; Glaucia Alessio Diniz; Roberto Araújo Montoya; João Carlos Pinto Dias; José Rodrigues Coura; George Luiz Lins Machado-Coelho; Pedro Albajar-Viñas; Rosália Morais Torres; Marta de Lana
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-11       Impact factor: 2.743

5.  Therapy of chagas disease: implications for levels of prevention.

Authors:  Sergio Sosa-Estani; Lisandro Colantonio; Elsa Leonor Segura
Journal:  J Trop Med       Date:  2012-03-05

Review 6.  Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.

Authors:  Yanina Sguassero; Cristina B Cuesta; Karen N Roberts; Elizabeth Hicks; Daniel Comandé; Agustín Ciapponi; Sergio Sosa-Estani
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

7.  Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure.

Authors:  Fernando J Sánchez-Valdéz; Angel Padilla; Wei Wang; Dylan Orr; Rick L Tarleton
Journal:  Elife       Date:  2018-03-26       Impact factor: 8.140

8.  Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis.

Authors:  Clara Crespillo-Andújar; Emmanuele Venanzi-Rullo; Rogelio López-Vélez; Begoña Monge-Maillo; Francesca Norman; Ana López-Polín; José A Pérez-Molina
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.228

9.  The challenges of Chagas Disease-- grim outlook or glimmer of hope.

Authors:  Rick L Tarleton; Richard Reithinger; Julio A Urbina; Uriel Kitron; Ricardo E Gürtler
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

Review 10.  Experimental and Clinical Treatment of Chagas Disease: A Review.

Authors:  Policarpo Ademar Sales Junior; Israel Molina; Silvane Maria Fonseca Murta; Adrián Sánchez-Montalvá; Fernando Salvador; Rodrigo Corrêa-Oliveira; Cláudia Martins Carneiro
Journal:  Am J Trop Med Hyg       Date:  2017-10-10       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.